Navigation Links
Strategic Agreement Launches Novel Drug Development Model
Date:9/7/2012

North America."

PCCA provides a variety of products and services to its member compounding pharmacies, which work directly with prescribers to provide patients with specialized medications that are not available in either over-the-counter or prescription form. For the past 30 years, PCCA has been focused on supporting independent pharmacies by delivering a complete portfolio of compounding products, services, education and intellectual property.

PCCA has led in the research, development and study of topical and transdermal technology including its Lipoderm® family of topical bases —the industry's only bases proven to deliver four drugs simultaneously. 

Jim Smith, president of PCCA added: "Through this agreement, we will leverage our knowledge and products to bring new drugs to the market and ultimately heighten awareness and acceptance of topical drug delivery. By building bridges between compounding pharmacists and drug manufacturers, our members will be best positioned to strengthen the role of independent pharmacies in their communities while continuing to play their crucial role in personalized medicine. We are convinced this new model for the development of drugs is an important advancement for the pharmaceutical industry."

Imprimis drug-development strategy calls for repurposing or reformatting existing FDA-approved generic drugs to create new high-value FDA-approved manufactured drugs that address new therapeutic applications. In other words, generic drugs would be combined with Imprimis' patented delivery-technology to create entirely new medications for specific markets that are lacking these medicines.

"Once a potential new drug application has been identified, prior to making an investment, we hope to be able to identify the correct formulation and dosing to protect our investment in new patent applications," said Baum. "We plan to implement a clinical development and a thoughtful regulatory
'/>"/>

SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
3. Herborium Announces Continuing Progress In Key Strategic Initiatives
4. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
5. UBM Canon, the Global MedTech Authority, Announces Strategic Alliance with ITG Market Research, a Preeminent Industry Research Organization
6. Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
7. VitaTech Adds New Capacity for Production and Customer Interface, Attributes Growth to Strategic Customer Partnerships
8. Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Sign Strategic Alliance to Further Cancer Research
9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
10. Medifast Announces International Expansion Into Mexico Through Strategic Partnership with Medix
11. Dehaier Medical Announces Strategic Mutual Cooperation Agreement with HEYER Medical AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Oct. 2, 2014   Softworld, Inc. announced today ... practice solely focused on the specific needs of pharmaceutical, ... Softworld has already been highly successful in the clinical ... capabilities to support the quality, regulatory, and validation space. ... a combination of the current Biometric team and the ...
(Date:10/2/2014)... 2, 2014   Mast Therapeutics, Inc. (NYSE ... Edwin L. Parsley , D.O. has joined the ... President.  Dr. Parsley has been actively engaged ... in February 2014.  He has served as Mast,s interim ... Medical Officer of Aires since April 2011.  Dr. Parsley ...
(Date:10/2/2014)... BOSTON , Oct. 1, 2014   Intarcia ... two of its four phase 3 clinical trials for ... through a matchstick-sized, subcutaneous osmotic mini-pump). The first trial, ... that tested the efficacy and safety of ITCA 650 ... study demonstrated ITCA 650 to be significantly superior to ...
Breaking Medicine Technology:Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5
... June 20, 2011 Boston Scientific Corporation (NYSE: ... its Mustang™ PTA Balloon Catheter, a highly deliverable 0.035 ... wide range of peripheral angioplasty procedures.  The Company plans ... and other international markets. Boston Scientific ...
... Panacea Global Inc., ("the Company") (OTCQB: PANG), a biopharmaceutical ... diagnose and monitor cancer, today announced the change of the ... On June 15, 2011, the trading symbol for the Company,s ... was changed from MLXG to PANG.  This change was made ...
Cached Medicine Technology:Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter 2Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter 3Panacea Global, Inc. Files Form 8-K to Announce Name Change; Trading Symbol Changes from MLXG to PANG 2
(Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
(Date:10/1/2014)... shown that more than 80 per cent of bowel ... study found that medicines called ,JAK inhibitors, halted tumour ... is present in more than 80 per cent of ... are in clinical trials, for diseases including rheumatoid arthritis, ... is the second-most common cancer in Australia with nearly ...
(Date:10/1/2014)... New research co-funded by the Engineering and Physical ... cyber-security of the UK,s vital industrial control systems ... the electricity grid, and the rail network. ... threats from hackers or malware infiltrating the systems ... Research Institute in Trustworthy Industrial Control Systems (RITICS), ...
(Date:10/1/2014)... suggests the adage that encourages people to keep their ... it comes to exercise. When walking, staying focused on ... it appear shorter and help people walk there faster, ... technique to walking while looking around the environment naturally, ... exercise. , "People are less interested in exercise if ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
Breaking Medicine News(10 mins):Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2
... New findings about brain rhythms could lead to the development ... team at Massachusetts General Hospital found that a brain rhythm ... form during sleep, where it becomes more intense at certain ... being awakened by noise or other disturbances. To test ...
... (ASM) will hold its 111th General Meeting May ... meeting will feature approximately 3,000 individual scientific presentations ... expected attendance of 10,000. Microbiologists study living ... critical to human and animal health, agriculture, the ...
... a common but painful deformity of the foot, are more likely ... found. And the more severe the bunion, the more likely ... body, leading to declines in both general and foot-specific health-related quality ... develops on the side of the big toe as it leans ...
... have discovered that a natural product isolated from a traditional ... lei gong teng, and used for hundreds of years to ... control machinery in the cell. The report, published as a ... Biology, suggests that the natural product could be a ...
... HealthDay Reporter , THURSDAY, March 3 (HealthDay News) ... painkillers experience cognitive problems such as confusion, disorientation and ... cancer patients from 17 health-care centers around Europe indicated ... morphine scored lower on observer-rated mental tests measuring orientation ...
... vast literature on cancer to produce a next-generation view ... cells. These hallmarks of the disease provide a ... influence biomedical researchers in their quest for new cancer ... Hanahan of cole Polytechnique Fdrale in Switzerland and Robert ...
Cached Medicine News:Health News:Particular Brain Rhythm in Sleep Makes You More Vulnerable to Disturbances 2Health News:American Society for Microbiology to host 111th General Meeting in New Orleans 2Health News:Solving a traditional Chinese medicine mystery 2Health News:Solving a traditional Chinese medicine mystery 3Health News:Study Finds Third of Cancer Patients on Opioids Are Confused 2Health News:Study Finds Third of Cancer Patients on Opioids Are Confused 3Health News:In search of cancer's common ground: A next-generation view 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: